My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 104

    1.

    Cost-effectiveness of surgically induced weight loss for the management of type 2 diabetes: modeled lifetime analysis.

    Keating CL, Dixon JB, Moodie ML, Peeters A, Bulfone L, Maglianno DJ, O'Brien PE.

    Diabetes Care. 2009 Apr;32(4):567-74. Epub 2009 Jan 26.PMID: 19171720 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Cost-efficacy of surgically induced weight loss for the management of type 2 diabetes: a randomized controlled trial.

    Keating CL, Dixon JB, Moodie ML, Peeters A, Playfair J, O'Brien PE.

    Diabetes Care. 2009 Apr;32(4):580-4. Epub 2009 Jan 26.PMID: 19171726 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study.

    Gaede P, Valentine WJ, Palmer AJ, Tucker DM, Lammert M, Parving HH, Pedersen O.

    Diabetes Care. 2008 Aug;31(8):1510-5. Epub 2008 Apr 28.PMID: 18443195 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.

    Shearer AT, Bagust A, Ampudia-Blasco FJ, Martínez-Lage Alvarez B, Pérez Escolano I, París G.

    Pharmacoeconomics. 2006;24 Suppl 1:49-59. Review.PMID: 16800162 [PubMed - indexed for MEDLINE]Related articles

    5.

    Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland.

    Brändle M, Azoulay M, Greiner RA.

    Int J Clin Pharmacol Ther. 2007 Apr;45(4):203-20.PMID: 17474539 [PubMed - indexed for MEDLINE]Related articles

    6.

    Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.

    Palmer JL, Gibbs M, Scheijbeler HW, Kotchie RW, Nielsen S, White J, Valentine WJ.

    Adv Ther. 2008 Aug;25(8):752-74.PMID: 18704282 [PubMed - indexed for MEDLINE]Related articles

    7.

    The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease - a UK collaborative study. The REFLUX trial.

    Grant A, Wileman S, Ramsay C, Bojke L, Epstein D, Sculpher M, Macran S, Kilonzo M, Vale L, Francis J, Mowat A, Krukowski Z, Heading R, Thursz M, Russell I, Campbell M; REFLUX Trial Group.

    Health Technol Assess. 2008 Sep;12(31):1-181, iii-iv.PMID: 18796263 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia.

    Cohen N, Minshall ME, Sharon-Nash L, Zakrzewska K, Valentine WJ, Palmer AJ.

    Pharmacoeconomics. 2007;25(10):881-97.PMID: 17887808 [PubMed - indexed for MEDLINE]Related articles

    9.

    Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes.

    Rosen AB, Hamel MB, Weinstein MC, Cutler DM, Fendrick AM, Vijan S.

    Ann Intern Med. 2005 Jul 19;143(2):89-99.PMID: 16027450 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    The cost-effectiveness of screening for type 2 diabetes. CDC Diabetes Cost-Effectiveness Study Group, Centers for Disease Control and Prevention.

    [No authors listed]

    JAMA. 1998 Nov 25;280(20):1757-63. Erratum in: JAMA 1999 Jan 27;281(4):325. PMID: 9842951 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data.

    Yu AP, Wu EQ, Birnbaum HG, Emani S, Fay M, Pohl G, Wintle M, Yang E, Oglesby A.

    Curr Med Res Opin. 2007 Sep;23(9):2157-69. Review.PMID: 17669232 [PubMed - indexed for MEDLINE]Related articles

    12.

    Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK.

    Beale S, Bagust A, Shearer AT, Martin A, Hulme L.

    Pharmacoeconomics. 2006;24 Suppl 1:21-34. Review.PMID: 16800160 [PubMed - indexed for MEDLINE]Related articles

    13.

    Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.

    Tunis SL, Minshall ME, Conner C, McCormick JI, Kapor J, Yale JF, Groleau D.

    Curr Med Res Opin. 2009 May;25(5):1273-84.PMID: 19366302 [PubMed - indexed for MEDLINE]Related articles

    14.

    Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.

    CDC Diabetes Cost-effectiveness Group.

    JAMA. 2002 May 15;287(19):2542-51.PMID: 12020335 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.

    Valentine WJ, Bottomley JM, Palmer AJ, Brändle M, Foos V, Williams R, Dormandy JA, Yates J, Tan MH, Massi-Benedetti M; PROactive Study Group.

    Diabet Med. 2007 Sep;24(9):982-1002. Epub 2007 Jun 25.PMID: 17593245 [PubMed - indexed for MEDLINE]Related articles

    16.

    Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus.

    Maetzel A, Ruof J, Covington M, Wolf A.

    Pharmacoeconomics. 2003;21(7):501-12.PMID: 12696990 [PubMed - indexed for MEDLINE]Related articles

    17.

    An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes.

    Ramsey SD, Clarke LD, Roberts CS, Sullivan SD, Johnson SJ, Liu LZ.

    Pharmacoeconomics. 2008;26(4):329-39.PMID: 18370567 [PubMed - indexed for MEDLINE]Related articles

    18.

    Cost-effectiveness of automated telephone self-management support with nurse care management among patients with diabetes.

    Handley MA, Shumway M, Schillinger D.

    Ann Fam Med. 2008 Nov-Dec;6(6):512-8.PMID: 19001303 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Cost-effectiveness of rosiglitazone oral combination for the treatment of type 2 diabetes in Germany.

    Shearer AT, Bagust A, Liebl A, Schoeffski O, Goertz A.

    Pharmacoeconomics. 2006;24 Suppl 1:35-48. Review.PMID: 16800161 [PubMed - indexed for MEDLINE]Related articles

    20.

    A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.

    Tilden DP, Mariz S, O'Bryan-Tear G, Bottomley J, Diamantopoulos A.

    Pharmacoeconomics. 2007;25(1):39-54. Erratum in: Pharmacoeconomics. 2007;25(3):237. PMID: 17192117 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity